Traders Buy Large Volume of Pfizer Put Options (PFE)
Pfizer (NYSE:PFE) was the recipient of some unusual options trading activity on Monday. Stock investors acquired 13,831 put options on the company, Analyst Ratings.Net reports. This is an increase of 146% compared to the typical daily volume of 5,618 put options.
In other Pfizer news, EVP Freda Lewis-Hall sold 38,461 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $28.70, for a total transaction of $1,103,830.70. Following the completion of the transaction, the executive vice president now directly owns 118,383 shares in the company, valued at approximately $3,397,592. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on PFE shares. Analysts at Jefferies Group cut their price target on shares of Pfizer (NYSE:PFE) from $31.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Pfizer (NYSE:PFE) to $28.50 in a research note to investors on Tuesday, September 3rd. They now have a “market perform” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer (NYSE:PFE) in a research note to investors on Monday, September 2nd. They now have a $30.00 price target on the stock.
Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $30.50.
Shares of Pfizer (NYSE:PFE) opened at 28.80 on Tuesday. Pfizer has a 52-week low of $23.55 and a 52-week high of $31.15. The stock’s 50-day moving average is $28.60 and its 200-day moving average is $28.83. The company has a market cap of $190.7 billion and a P/E ratio of 7.99.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was down 7.1% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.16 earnings per share for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.